Last reviewed · How we verify

NCT00519675

Open Label Treatment of Patients With Chronic Hand Dermatitis Who Have Participated in a Previous Clinical Trial Involving Oral Alitretinoin

Completed Phase 3 Last updated 9 May 2023
What this trial tests

Phase 3 trial testing alitretinoin in Eczema in 150 participants. Completed.

Timeline
1 May 2007

Quick facts

Lead sponsorBasilea Pharmaceutica
PhasePhase 3
StatusCompleted
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposetreatment
Enrollment150
Start date1 May 2007
Sites4 locations across France, Germany

Drugs / interventions tested

Conditions studied

Sponsor

Basilea Pharmaceutica — full company profile →

Who can join

Adults 18 to 80, any sex, with Eczema. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Sponsor's own description

The purpose of the study is to investigate the safety and efficacy of alitretinoin in chronic hand eczema that is refractory to topical corticosteroids.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Retinoids as Chemo-Preventive and Molecular-Targeted Anti-Cancer Therapies.
    Hunsu VO, Facey COB, Fields JZ, Boman BM. · · 2021 · cited 62× · PMID 34299349 · DOI 10.3390/ijms22147731

Verify or expand the search:

Other trials of alitretinoin

Trials testing the same drug.

Other recruiting trials for Eczema

Currently open trials in the same condition.

Other Basilea Pharmaceutica trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00519675.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing